New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
08:50 EDTRPRXRepros Therapeutics weakness creates buying opportunity, says Roth Capital
After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
12:46 EDTRPRXRepros Therapeutics volatility at low end of six-month range
Repros Therapeutics overall option implied volatility of 102 compares to its 26-week average of 111 according to Track Data, suggesting decreasing price movement.
November 13, 2014
10:44 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
November 12, 2014
10:34 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI RPRX KATE PNK CZR KING TSLA UBNT LOCO GNRC
November 11, 2014
10:39 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
November 10, 2014
10:17 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:04 EDTRPRXRepros Therapeutics reports Q3 EPS 32c, consensus (39c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use